{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:29:20Z","timestamp":1794313760017,"version":"4.9.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Steve and Genevieve Jurvetson and the Sergey Brin Family Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD), depression and anxiety. Special Operations Forces (SOF) veterans (SOVs) may be at an elevated risk for these complications, leading some to seek underexplored treatment alternatives such as the oneirogen ibogaine, a plant-derived compound known to interact with multiple neurotransmitter systems that has been studied primarily as a treatment for substance use disorders. Ibogaine has been associated with instances of fatal cardiac arrhythmia, but coadministration of magnesium may mitigate this concern. In the present study, we report a prospective observational study of the Magnesium\u2013Ibogaine: the Stanford Traumatic Injury to the CNS protocol (MISTIC), provided together with complementary treatment modalities, in 30 male SOVs with predominantly mild TBI. We assessed changes in the World Health Organization Disability Assessment Schedule from baseline to immediately (primary outcome) and 1\u2009month (secondary outcome) after treatment. Additional secondary outcomes included changes in PTSD (Clinician-Administered PTSD Scale for DSM-5), depression (Montgomery\u2013\u00c5sberg Depression Rating Scale) and anxiety (Hamilton Anxiety Rating Scale). MISTIC resulted in significant improvements in functioning both immediately (\n                    <jats:italic>P<\/jats:italic>\n                    <jats:sub>corrected<\/jats:sub>\n                    \u2009&lt;\u20090.001, Cohen\u2019s\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u20090.74) and 1\u2009month (\n                    <jats:italic>P<\/jats:italic>\n                    <jats:sub>corrected<\/jats:sub>\n                    \u2009&lt; 0.001,\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u20092.20) after treatment and in PTSD (\n                    <jats:italic>P<\/jats:italic>\n                    <jats:sub>corrected<\/jats:sub>\n                    \u2009&lt;\u20090.001,\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u20092.54), depression (\n                    <jats:italic>P<\/jats:italic>\n                    <jats:sub>corrected<\/jats:sub>\n                    \u2009&lt;\u20090.001,\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u20092.80) and anxiety (\n                    <jats:italic>P<\/jats:italic>\n                    <jats:sub>corrected<\/jats:sub>\n                    \u2009&lt;\u20090.001,\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u20092.13) at 1\u2009month after treatment. There were no unexpected or serious adverse events. Controlled clinical trials to assess safety and efficacy are needed to validate these initial open-label findings. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04313712\">NCT04313712<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02705-w","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T06:03:32Z","timestamp":1704434612000},"page":"373-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Magnesium\u2013ibogaine therapy in veterans with traumatic brain injuries"],"prefix":"10.1038","volume":"30","author":[{"given":"Kirsten N.","family":"Cherian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-3406","authenticated-orcid":false,"given":"Jackob N.","family":"Keynan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-217X","authenticated-orcid":false,"given":"Lauren","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afik","family":"Faerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Shamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Or","family":"Keynan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Coetzee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Batail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Bassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Sahlem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Inzunza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9203-0730","authenticated-orcid":false,"given":"Jonathan","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. E.","family":"Rolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheen","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-4525","authenticated-orcid":false,"given":"Ian H.","family":"Kratter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-3203","authenticated-orcid":false,"given":"Nolan R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"2705_CR1","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S1474-4422(22)00309-X","volume":"21","author":"AIR Maas","year":"2022","unstructured":"Maas, A. I. R. et al. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol. 21, 1004\u20131060 (2022).","journal-title":"Lancet Neurol."},{"key":"2705_CR2","unstructured":"Traumatic Brain Injury. US Department of Veterans Afffairs publichealth.va.gov\/exposures\/traumatic-brain-injury.asp (2022)."},{"key":"2705_CR3","first-page":"S242","volume":"10","author":"AC McKee","year":"2014","unstructured":"McKee, A. C. & Robinson, M. E. Military-related traumatic brain injury and neurodegeneration. Alzheimers Dement. J. Alzheimers Assoc. 10, S242\u2013S253 (2014).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"2705_CR4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1474-4422(08)70032-2","volume":"7","author":"P Hayward","year":"2008","unstructured":"Hayward, P. Traumatic brain injury: the signature of modern conflicts. Lancet Neurol. 7, 200\u2013201 (2008).","journal-title":"Lancet Neurol."},{"key":"2705_CR5","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJM198712243172604","volume":"317","author":"JE Helzer","year":"1987","unstructured":"Helzer, J. E., Robins, L. N. & McEvoy, L. Post-traumatic stress disorder in the general population. N. Engl. J. Med. 317, 1630\u20131634 (1987).","journal-title":"N. Engl. J. Med."},{"key":"2705_CR6","doi-asserted-by":"crossref","first-page":"100491","DOI":"10.1016\/j.conctc.2019.100491","volume":"17","author":"DC Beidel","year":"2020","unstructured":"Beidel, D. C. et al. Trauma management therapy and prolonged exposure therapy for PTSD in an active duty sample: design and methodology of a randomized clinical trial. Contemp. Clin. Trials Commun. 17, 100491 (2020).","journal-title":"Contemp. Clin. Trials Commun."},{"key":"2705_CR7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1037\/tra0000290","volume":"10","author":"CJ Bryan","year":"2018","unstructured":"Bryan, C. J. Moral injury, posttraumatic stress disorder, and suicidal behavior among National Guard personnel. Psychol. Trauma Theory Res. Pract. Policy 10, 36 (2018).","journal-title":"Psychol. Trauma Theory Res. Pract. Policy"},{"key":"2705_CR8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/jama.2019.20825","volume":"323","author":"MM Steenkamp","year":"2020","unstructured":"Steenkamp, M. M., Litz, B. T. & Marmar, C. R. First-line psychotherapies for military-related PTSD. JAMA 323, 656\u2013657 (2020).","journal-title":"JAMA"},{"key":"2705_CR9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jama.2015.8370","volume":"314","author":"MM Steenkamp","year":"2015","unstructured":"Steenkamp, M. M., Litz, B. T., Hoge, C. W. & Marmar, C. R. Psychotherapy for military-related PTSD: a review of randomized clinical trials. JAMA 314, 489\u2013500 (2015).","journal-title":"JAMA"},{"key":"2705_CR10","first-page":"32","volume":"37","author":"W Alexander","year":"2012","unstructured":"Alexander, W. Pharmacotherapy for post-traumatic stress disorder in combat veterans. Pharm. Ther. 37, 32\u201338 (2012).","journal-title":"Pharm. Ther."},{"key":"2705_CR11","unstructured":"Inoue, C., Shawler, E., Jordan, C. H. & Jackson, C. A. Veteran and military mental health issues. StatPearls https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572092\/ (2022)."},{"key":"2705_CR12","doi-asserted-by":"crossref","first-page":"S-53","DOI":"10.1089\/neu.2016.4709","volume":"34","author":"ME Robinson","year":"2017","unstructured":"Robinson, M. E., Clark, D. C., Milberg, W. P., McGlinchey, R. E. & Salat, D. H. Characterization of differences in functional connectivity associated with close-range blast exposure. J. Neurotrauma 34, S-53\u2013S-61 (2017).","journal-title":"J. Neurotrauma"},{"key":"2705_CR13","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1089\/neu.2020.7141","volume":"37","author":"JR Stone","year":"2020","unstructured":"Stone, J. R. et al. Functional and structural neuroimaging correlates of repetitive low-level blast exposure in career breachers. J. Neurotrauma 37, 2468\u20132481 (2020).","journal-title":"J. Neurotrauma"},{"key":"2705_CR14","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1089\/neu.2012.2683","volume":"30","author":"CM Tate","year":"2013","unstructured":"Tate, C. M. et al. Serum brain biomarker level, neurocognitive performance, and self-reported symptom changes in soldiers repeatedly exposed to low-level blast: a Breacher Pilot Study. J. Neurotrauma 30, 1620\u20131630 (2013).","journal-title":"J. Neurotrauma"},{"key":"2705_CR15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/13854046.2017.1390163","volume":"32","author":"K Donnelly","year":"2018","unstructured":"Donnelly, K., Donnelly, J. P., Warner, G. C., Kittleson, C. J. & King, P. R. Longitudinal study of objective and subjective cognitive performance and psychological distress in OEF\/OIF Veterans with and without traumatic brain injury. Clin. Neuropsychol. 32, 436\u2013455 (2018).","journal-title":"Clin. Neuropsychol."},{"key":"2705_CR16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1682\/JRRD.2013.10.0226","volume":"51","author":"LM French","year":"2014","unstructured":"French, L. M., Lange, R. T. & Brickell, T. A. Subjective cognitive complaints and neuropsychological test performance following military-related traumatic brain injury. J. Rehabil. Res. Dev. 51, 933\u2013949 (2014).","journal-title":"J. Rehabil. Res. Dev."},{"key":"2705_CR17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s11065-014-9271-8","volume":"24","author":"JE Karr","year":"2014","unstructured":"Karr, J. E., Areshenkoff, C. N., Duggan, E. C. & Garcia-Barrera, M. A. Blast-related mild traumatic brain injury: a Bayesian random-effects meta-analysis on the cognitive outcomes of concussion among military personnel. Neuropsychol. Rev. 24, 428\u2013444 (2014).","journal-title":"Neuropsychol. Rev."},{"key":"2705_CR18","doi-asserted-by":"crossref","first-page":"E382","DOI":"10.1097\/HTR.0000000000000557","volume":"35","author":"L Vos","year":"2020","unstructured":"Vos, L. et al. The discrepancy between cognitive complaints and neuropsychological test findings in persons with traumatic brain injury. J. Head. Trauma Rehabil. 35, E382\u2013E392 (2020).","journal-title":"J. Head. Trauma Rehabil."},{"key":"2705_CR19","doi-asserted-by":"crossref","first-page":"108717","DOI":"10.1016\/j.jsat.2021.108717","volume":"138","author":"P K\u00f6ck","year":"2022","unstructured":"K\u00f6ck, P., Froelich, K., Walter, M., Lang, U. & D\u00fcrsteler, K. M. A systematic literature review of clinical trials and therapeutic applications of ibogaine. J. Subst. Abus. Treat. 138, 108717 (2022).","journal-title":"J. Subst. Abus. Treat."},{"key":"2705_CR20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/15563650.2016.1138226","volume":"54","author":"RPW Litjens","year":"2016","unstructured":"Litjens, R. P. W. & Brunt, T. M. How toxic is ibogaine? Clin. Toxicol. 54, 297\u2013302 (2016).","journal-title":"Clin. Toxicol."},{"key":"2705_CR21","doi-asserted-by":"crossref","unstructured":"Corkery, J. M. in Progress in Brain Research Vol. 242 (ed. Calvey, T.) 217\u2013257 (Elsevier, 2018).","DOI":"10.1016\/bs.pbr.2018.08.005"},{"key":"2705_CR22","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1021\/acschemneuro.8b00294","volume":"9","author":"MJ Wasko","year":"2018","unstructured":"Wasko, M. J., Witt-Enderby, P. A. & Surratt, C. K. DARK classics in chemical neuroscience: ibogaine. ACS Chem. Neurosci. 9, 2475\u20132483 (2018).","journal-title":"ACS Chem. Neurosci."},{"key":"2705_CR23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fphar.2019.00193","volume":"10","author":"S Marton","year":"2019","unstructured":"Marton, S. et al. Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits. Front. Pharmacol. 10, 193 (2019).","journal-title":"Front. Pharmacol."},{"key":"2705_CR24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","volume":"589","author":"LP Cameron","year":"2021","unstructured":"Cameron, L. P. et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589, 474\u2013479 (2021).","journal-title":"Nature"},{"key":"2705_CR25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1037\/pha0000084","volume":"24","author":"A Garcia-Romeu","year":"2016","unstructured":"Garcia-Romeu, A., Kersgaard, B. & Addy, P. H. Clinical applications of hallucinogens: a review. Exp. Clin. Psychopharmacol. 24, 229\u2013268 (2016).","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"2705_CR26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/02791072.2019.1598603","volume":"51","author":"TK Brown","year":"2019","unstructured":"Brown, T. K., Noller, G. E. & Denenberg, J. O. Ibogaine and subjective experience: transformative states and psychopharmacotherapy in the treatment of opioid use disorder. J. Psychoact. Drugs 51, 155\u2013165 (2019).","journal-title":"J. Psychoact. Drugs"},{"key":"2705_CR27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1021\/acsptsci.0c00164","volume":"4","author":"J Gonz\u00e1lez","year":"2021","unstructured":"Gonz\u00e1lez, J. et al. EEG gamma band alterations and rem-like traits underpin the acute effect of the atypical psychedelic ibogaine in the rat. ACS Pharmacol. Transl. Sci. 4, 517\u2013525 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"2705_CR28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1556\/2054.01.2017.007","volume":"1","author":"EE Schenberg","year":"2017","unstructured":"Schenberg, E. E. et al. A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment. J. Psychedelic Stud. 1, 74\u201383 (2017).","journal-title":"J. Psychedelic Stud."},{"key":"2705_CR29","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00213-021-05964-y","volume":"239","author":"G Ona","year":"2022","unstructured":"Ona, G. et al. The adverse events of ibogaine in humans: an updated systematic review of the literature (2015\u20132020). Psychopharmacology 239, 1977\u20131987 (2022).","journal-title":"Psychopharmacology"},{"key":"2705_CR30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF03007798","volume":"28","author":"BS Krasner","year":"1981","unstructured":"Krasner, B. S., Girdwood, R. & Smith, H. The effect of slow releasing oral magnesium chloride on the QTc interval of the electrocardiogram during open heart surgery. Can. Anaesth. Soc. J. 28, 329\u2013333 (1981).","journal-title":"Can. Anaesth. Soc. J."},{"key":"2705_CR31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1592\/phco.23.3.296.32109","volume":"23","author":"MF Caron","year":"2003","unstructured":"Caron, M. F. et al. Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide. Pharmacotherapy 23, 296\u2013300 (2003).","journal-title":"Pharmacotherapy"},{"key":"2705_CR32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/00952990.2017.1320802","volume":"44","author":"TK Brown","year":"2018","unstructured":"Brown, T. K. & Alper, K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am. J. Drug Alcohol Abuse 44, 24\u201336 (2018).","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"2705_CR33","doi-asserted-by":"publisher","unstructured":"Armstrong, S. B. et al. Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans. Mil. Psychol. https:\/\/doi.org\/10.1080\/08995605.2022.2156200 (2023).","DOI":"10.1080\/08995605.2022.2156200"},{"key":"2705_CR34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/02791072.2017.1290855","volume":"49","author":"A Heink","year":"2017","unstructured":"Heink, A., Katsikas, S. & Lange-Altman, T. Examination of the phenomenology of the ibogaine treatment experience: role of altered states of consciousness and psychedelic experiences. J. Psychoact. Drugs 49, 201\u2013208 (2017).","journal-title":"J. Psychoact. Drugs"},{"key":"2705_CR35","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1177\/0269881114552713","volume":"28","author":"EE Schenberg","year":"2014","unstructured":"Schenberg, E. E., de Castro Comis, M. A., Chaves, B. R. & da Silveira, D. X. Treating drug dependence with the aid of ibogaine: a retrospective study. J. Psychopharmacol. 28, 993\u20131000 (2014).","journal-title":"J. Psychopharmacol."},{"key":"2705_CR36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpsychires.2021.05.019","volume":"139","author":"AN Siegel","year":"2021","unstructured":"Siegel, A. N. et al. Registered clinical studies investigating psychedelic drugs for psychiatric disorders. J. Psychiatr. Res. 139, 71\u201381 (2021).","journal-title":"J. Psychiatr. Res."},{"key":"2705_CR37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","volume":"44","author":"GE Noller","year":"2018","unstructured":"Noller, G. E., Frampton, C. M. & Yazar-Klosinski, B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am. J. Drug Alcohol Abuse 44, 37\u201346 (2018).","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"2705_CR38","doi-asserted-by":"crossref","first-page":"247054702093956","DOI":"10.1177\/2470547020939564","volume":"4","author":"AK Davis","year":"2020","unstructured":"Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P. & Amoroso, T. Psychedelic treatment for trauma-related psychological and cognitive impairment among US Special Operations Forces Veterans. Chronic Stress 4, 247054702093956 (2020).","journal-title":"Chronic Stress"},{"key":"2705_CR39","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/milmed\/usab347","volume":"187","author":"A Garcia","year":"2022","unstructured":"Garcia, A. et al. Neurobehavioral symptoms in U.S. Special Operations Forces in rehabilitation after traumatic brain injury: a TBI model systems study. Mil. Med. 187, 1412\u20131421 (2022).","journal-title":"Mil. Med."},{"key":"2705_CR40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0091217420906659","volume":"55","author":"BC Frueh","year":"2020","unstructured":"Frueh, B. C. et al. \u2018Operator syndrome\u2019: a unique constellation of medical and behavioral health-care needs of military special operation forces. Int. J. Psychiatry Med. 55, 281\u2013295 (2020).","journal-title":"Int. J. Psychiatry Med."},{"key":"2705_CR41","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1089\/neu.2022.0030","volume":"39","author":"BL Edlow","year":"2022","unstructured":"Edlow, B. L. et al. Long-term effects of repeated blast exposure in United States Special Operations Forces personnel: a pilot study protocol. J. Neurotrauma 39, 1391\u20131407 (2022).","journal-title":"J. Neurotrauma"},{"key":"2705_CR42","doi-asserted-by":"crossref","first-page":"E292","DOI":"10.1097\/HTR.0000000000000737","volume":"37","author":"A Garcia","year":"2022","unstructured":"Garcia, A. et al. Health conditions among Special Operations Forces versus conventional military service members: a VA TBI model systems study. J. Head. Trauma Rehabil. 37, E292\u2013E298 (2022).","journal-title":"J. Head. Trauma Rehabil."},{"key":"2705_CR43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/02699052.2020.1861656","volume":"35","author":"KL McIntire","year":"2021","unstructured":"McIntire, K. L. et al. Factors increasing risk of suicide after traumatic brain injury: a state-of-the-science review of military and civilian studies. Brain Inj. 35, 151\u2013163 (2021).","journal-title":"Brain Inj."},{"key":"2705_CR44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/02699052.2022.2033843","volume":"36","author":"DX Cifu","year":"2022","unstructured":"Cifu, D. X. Clinical research findings from the long-term impact of military-relevant brain injury consortium\u2014Chronic Effects of Neurotrauma Consortium (LIMBIC-CENC) 2013\u20132021. Brain Inj. 36, 587\u2013597 (2022).","journal-title":"Brain Inj."},{"key":"2705_CR45","unstructured":"Ustun, T. B., Kostanjesek, N., Chatterji, S., Rehm, J. & World Health Organization. Measuring Health and Disability: manual for WHO Disability Assessment Schedule (WHODAS-2.0) (WHO, 2010); apps.who.int\/iris\/handle\/10665\/43974"},{"key":"2705_CR46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1037\/pas0000486","volume":"30","author":"FW Weathers","year":"2018","unstructured":"Weathers, F. W. et al. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol. Assess. 30, 383\u2013395 (2018).","journal-title":"Psychol. Assess."},{"key":"2705_CR47","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery, S. A. & Asberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry J. Ment. Sci. 134, 382\u2013389 (1979).","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"2705_CR48","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archpsyc.1988.01800320058007","volume":"45","author":"JBW Williams","year":"1988","unstructured":"Williams, J. B. W. A structured interview guide for the Hamilton Depression Rating Scale. Arch. Gen. Psychiatry 45, 742 (1988).","journal-title":"Arch. Gen. Psychiatry"},{"key":"2705_CR49","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025\u20131033 (2021).","journal-title":"Nat. Med."},{"key":"2705_CR50","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jad.2016.12.041","volume":"210","author":"S Leucht","year":"2017","unstructured":"Leucht, S. et al. What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies. J. Affect. Disord. 210, 287\u2013293 (2017).","journal-title":"J. Affect. Disord."},{"key":"2705_CR51","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/da.20275","volume":"24","author":"A McIntyre","year":"2007","unstructured":"McIntyre, A., Gendron, A. & McIntyre, A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress. Anxiety 24, 487\u2013494 (2007).","journal-title":"Depress. Anxiety"},{"key":"2705_CR52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1037\/a0013659","volume":"23","author":"ML Rohling","year":"2009","unstructured":"Rohling, M. L., Faust, M. E., Beverly, B. & Demakis, G. Effectiveness of cognitive rehabilitation following acquired brain injury: a meta-analytic re-examination of Cicerone et al.\u2019s (2000, 2005) systematic reviews. Neuropsychology 23, 20\u201339 (2009).","journal-title":"Neuropsychology"},{"key":"2705_CR53","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3109\/02699052.2013.793396","volume":"27","author":"SU Bhalerao","year":"2013","unstructured":"Bhalerao, S. U. et al. Understanding the neuropsychiatric consequences associated with significant traumatic brain injury. Brain Inj. 27, 767\u2013774 (2013).","journal-title":"Brain Inj."},{"key":"2705_CR54","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11682-015-9440-2","volume":"9","author":"DB Cooper","year":"2015","unstructured":"Cooper, D. B. et al. Treatment of persistent post-concussive symptoms after mild traumatic brain injury: a systematic review of cognitive rehabilitation and behavioral health interventions in military service members and veterans. Brain Imaging Behav. 9, 403\u2013420 (2015).","journal-title":"Brain Imaging Behav."},{"key":"2705_CR55","doi-asserted-by":"crossref","first-page":"e2326296","DOI":"10.1001\/jamanetworkopen.2023.26296","volume":"6","author":"LA Brenner","year":"2023","unstructured":"Brenner, L. A. et al. Associations of military-related traumatic brain injury with new-onset mental health conditions and suicide risk. JAMA Netw. Open 6, e2326296 (2023).","journal-title":"JAMA Netw. Open"},{"key":"2705_CR56","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/jama.2018.10211","volume":"320","author":"T Madsen","year":"2018","unstructured":"Madsen, T. et al. Association between traumatic brain injury and risk of suicide. JAMA 320, 580\u2013588 (2018).","journal-title":"JAMA"},{"key":"2705_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0051-2","volume":"5","author":"G Turecki","year":"2019","unstructured":"Turecki, G. et al. Suicide and suicide risk. Nat. Rev. Dis. Prim. 5, 1\u201322 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2705_CR58","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.1995","volume":"62","author":"KW Smith","year":"2022","unstructured":"Smith, K. W., Sicignano, D. J., Hernandez, A. V. & White, C. M. MDMA\u2010assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review with meta\u2010analysis. J. Clin. Pharmacol. 62, 463\u2013471 (2022).","journal-title":"J. Clin. Pharmacol."},{"key":"2705_CR59","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15070","author":"S Tedesco","year":"2021","unstructured":"Tedesco, S. et al. The efficacy of MDMA (3,4-methylenedioxymethamphetamine) for post-traumatic stress disorder in humans: a systematic review and meta-analysis. Cureus https:\/\/doi.org\/10.7759\/cureus.15070 (2021).","journal-title":"Cureus"},{"key":"2705_CR60","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz, M. P. et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 79, 953\u2013962 (2022).","journal-title":"JAMA Psychiatry"},{"key":"2705_CR61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235, 399\u2013408 (2018).","journal-title":"Psychopharmacology"},{"key":"2705_CR62","doi-asserted-by":"crossref","first-page":"112749","DOI":"10.1016\/j.psychres.2020.112749","volume":"284","author":"SB Goldberg","year":"2020","unstructured":"Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L. & Hutson, P. R. The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. Psychiatry Res. 284, 112749 (2020).","journal-title":"Psychiatry Res."},{"key":"2705_CR63","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637\u20131648 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2705_CR64","doi-asserted-by":"publisher","unstructured":"Holze, F., Gasser, P., M\u00fcller, F., Dolder, P. C. & Liechti, M. E. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol. Psychiatry https:\/\/doi.org\/10.1016\/j.biopsych.2022.08.025 (2022).","DOI":"10.1016\/j.biopsych.2022.08.025"},{"key":"2705_CR65","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes, F. et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol. Med. 49, 655\u2013663 (2019).","journal-title":"Psychol. Med."},{"key":"2705_CR66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches, R. F. et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J. Clin. Psychopharmacol. 36, 77\u201381 (2016).","journal-title":"J. Clin. Psychopharmacol."},{"key":"2705_CR67","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1089\/acm.2009.0510","volume":"16","author":"SJW Smeeding","year":"2010","unstructured":"Smeeding, S. J. W., Bradshaw, D. H., Kumpfer, K., Trevithick, S. & Stoddard, G. J. Outcome evaluation of the Veterans Affairs Salt Lake City integrative health clinic for chronic pain and stress-related depression, anxiety, and post-traumatic stress disorder. J. Altern. Complement. Med. 16, 823\u2013835 (2010).","journal-title":"J. Altern. Complement. Med."},{"key":"2705_CR68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1089\/ict.2022.29042.gbe","volume":"28","author":"G Bettes","year":"2022","unstructured":"Bettes, G. et al. Examining the efficacy and feasibility of a residential retreat program for first responders and veterans with posttraumatic stress disorder: a pilot study. Integr. Complement. Ther. 28, 212\u2013220 (2022).","journal-title":"Integr. Complement. Ther."},{"key":"2705_CR69","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s00213-021-05817-8","volume":"238","author":"MV Uthaug","year":"2021","unstructured":"Uthaug, M. V. et al. A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology 238, 1899\u20131910 (2021).","journal-title":"Psychopharmacology"},{"key":"2705_CR70","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/13854046.2012.680913","volume":"26","author":"M Calamia","year":"2012","unstructured":"Calamia, M., Markon, K. & Tranel, D. Scoring higher the second time around: meta-analyses of practice effects in neuropsychological assessment. Clin. Neuropsychol. 26, 543\u2013570 (2012).","journal-title":"Clin. Neuropsychol."},{"key":"2705_CR71","doi-asserted-by":"crossref","first-page":"e0130492","DOI":"10.1371\/journal.pone.0130492","volume":"10","author":"KA Schwarz","year":"2015","unstructured":"Schwarz, K. A. & B\u00fcchel, C. Cognition and the placebo effect\u2014dissociating subjective perception and actual performance. PLoS ONE 10, e0130492 (2015).","journal-title":"PLoS ONE"},{"key":"2705_CR72","doi-asserted-by":"crossref","first-page":"e2209308119","DOI":"10.1073\/pnas.2209308119","volume":"119","author":"J Parong","year":"2022","unstructured":"Parong, J., Seitz, A. R., Jaeggi, S. M. & Green, C. S. Expectation effects in working memory training. Proc. Natl Acad. Sci. USA 119, e2209308119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2705_CR73","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0306-4522(93)90500-F","volume":"55","author":"E O\u2019Hearn","year":"1993","unstructured":"O\u2019Hearn, E. & Molliver, M. E. Degeneration of purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 55, 303\u2013310 (1993).","journal-title":"Neuroscience"},{"key":"2705_CR74","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/13803395.2011.614599","volume":"34","author":"CJ O\u2019Halloran","year":"2012","unstructured":"O\u2019Halloran, C. J., Kinsella, G. J. & Storey, E. The cerebellum and neuropsychological functioning: a critical review. J. Clin. Exp. Neuropsychol. 34, 35\u201356 (2012).","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"2705_CR75","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1093\/brain\/awr266","volume":"134","author":"AM Tedesco","year":"2011","unstructured":"Tedesco, A. M. et al. The cerebellar cognitive profile. Brain J. Neurol. 134, 3672\u20133686 (2011).","journal-title":"Brain J. Neurol."},{"key":"2705_CR76","first-page":"103","volume":"1","author":"TE Goldberg","year":"2015","unstructured":"Goldberg, T. E., Harvey, P. D., Wesnes, K. A., Snyder, P. J. & Schneider, L. S. Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer\u2019s disease randomized controlled trials. Alzheimers Dement. 1, 103\u2013111 (2015).","journal-title":"Alzheimers Dement."},{"key":"2705_CR77","unstructured":"Sherman, E., Tan, J. E., & Hrabok, M. A Compendium of Neuropsychological Tests: Fundamentals of Neuropsychological Assessment and Test Reviews for Clinical Practice (Oxford Univ. Press, 2022)."},{"key":"2705_CR78","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3, 619\u2013627 (2016).","journal-title":"Lancet Psychiatry"},{"key":"2705_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02455-9","author":"SK Peck","year":"2023","unstructured":"Peck, S. K. et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-023-02455-9 (2023).","journal-title":"Nat. Med."},{"key":"2705_CR80","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","volume":"67","author":"M aan het Rot","year":"2010","unstructured":"aan het Rot, M. et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 67, 139\u2013145 (2010).","journal-title":"Biol. Psychiatry"},{"key":"2705_CR81","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000457960","volume":"86","author":"ST Wilkinson","year":"2017","unstructured":"Wilkinson, S. T. et al. Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother. Psychosom. 86, 162\u2013167 (2017).","journal-title":"Psychother. Psychosom."},{"key":"2705_CR82","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis, A. K. et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78, 481 (2021).","journal-title":"JAMA Psychiatry"},{"key":"2705_CR83","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","volume":"71","author":"CA Zarate","year":"2012","unstructured":"Zarate, C. A. et al. Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 71, 939\u2013946 (2012).","journal-title":"Biol. Psychiatry"},{"key":"2705_CR84","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.biopsych.2008.08.014","volume":"65","author":"G Salvadore","year":"2009","unstructured":"Salvadore, G. et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol. Psychiatry 65, 289\u2013295 (2009).","journal-title":"Biol. Psychiatry"},{"key":"2705_CR85","unstructured":"Women in Special Operations: Improvements to Policy, Data, and Assessments Needed to Better Understand and Address Career Barriers (US GAO, 2023); gao.gov\/products\/gao-23-105168"},{"key":"2705_CR86","unstructured":"Barriers to Minority Participation in Special Operations (RAND Corporation, 1999); scholar.google.com\/scholar?hl=en&as_sdt=0%2C5&q=Barriers+to+Minority+Participation+in+Special+Operations+Forces.&btnG ="},{"key":"2705_CR87","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4085\/1062-6050-297-18","volume":"55","author":"J Cunningham","year":"2020","unstructured":"Cunningham, J., Broglio, S. P., O\u2019Grady, M. & Wilson, F. History of sport-related concussion and long-term clinical cognitive health outcomes in retired athletes: a systematic review. J. Athl. Train. 55, 132\u2013158 (2020).","journal-title":"J. Athl. Train."},{"key":"2705_CR88","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3389\/fneur.2019.01345","volume":"10","author":"BL Brett","year":"2020","unstructured":"Brett, B. L. et al. The association between persistent white-matter abnormalities and repeat injury after sport-related concussion. Front. Neurol. 10, 1345 (2020).","journal-title":"Front. Neurol."},{"key":"2705_CR89","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2018.01.049","volume":"142","author":"DJ Heal","year":"2018","unstructured":"Heal, D. J., Gosden, J. & Smith, S. L. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. Neuropharmacology 142, 89\u2013115 (2018).","journal-title":"Neuropharmacology"},{"key":"2705_CR90","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/01.HTR.0000300227.67748.77","volume":"22","author":"JD Corrigan","year":"2007","unstructured":"Corrigan, J. D. & Bogner, J. Initial reliability and validity of the Ohio State University TBI identification method. J. Head. Trauma Rehabil. 22, 318\u2013329 (2007).","journal-title":"J. Head. Trauma Rehabil."},{"key":"2705_CR91","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/HTR.0b013e3182865859","volume":"29","author":"CB Fortier","year":"2014","unstructured":"Fortier, C. B. et al. The Boston Assessment of Traumatic Brain Injury\u2013Lifetime (BAT-L) semistructured interview: evidence of research utility and validity. J. Head. Trauma Rehabil. 29, 89 (2014).","journal-title":"J. Head. Trauma Rehabil."},{"key":"2705_CR92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0099-9598(01)56005-8","volume":"56","author":"KR Alper","year":"2001","unstructured":"Alper, K. R. Ibogaine: a review. Alkaloids Chem. Biol. 56, 1\u201338 (2001).","journal-title":"Alkaloids Chem. Biol."},{"key":"2705_CR93","doi-asserted-by":"crossref","unstructured":"Diagnostic and Statistical Manual of Mental Disorders, 5th edn (American Psychiatric Association, 2013).","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"Suppl. 20","key":"2705_CR94","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan, D. V. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59(Suppl. 20), 22\u201333 (1998).","journal-title":"J. Clin. Psychiatry"},{"key":"2705_CR95","unstructured":"First, M. B., Williams, J. B. W., Karg, R. S. & Spitzer, R. L. Structured Clinical Interview for DSM-5\u2014Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV) (American Psychiatric Association, 2015)."},{"key":"2705_CR96","first-page":"53","volume":"1","author":"TM Keane","year":"1989","unstructured":"Keane, T. M. et al. Clinical evaluation of a measure to assess combat exposure. Psychol. Assess. J. Consult. Clin. Psychol. 1, 53 (1989).","journal-title":"Psychol. Assess. J. Consult. Clin. Psychol."},{"key":"2705_CR97","first-page":"9","volume":"42","author":"LH Gold","year":"2014","unstructured":"Gold, L. H. DSM-5 and the assessment of functioning: the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). J. Am. Acad. Psychiatry Law 42, 9 (2014).","journal-title":"J. Am. Acad. Psychiatry Law"},{"key":"2705_CR98","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0165-0327(02)00120-9","volume":"77","author":"MJ M\u00fcller","year":"2003","unstructured":"M\u00fcller, M. J., Himmerich, H., Kienzle, B. & Szegedi, A. Differentiating moderate and severe depression using the Montgomery\u2013\u00c5sberg depression rating scale (MADRS). J. Affect. Disord. 77, 255\u2013260 (2003).","journal-title":"J. Affect. Disord."},{"key":"2705_CR99","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/da.1033","volume":"13","author":"MK Shear","year":"2001","unstructured":"Shear, M. K. et al. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress. Anxiety 13, 166\u2013178 (2001).","journal-title":"Depress. Anxiety"},{"key":"2705_CR100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/mpr.323","volume":"19","author":"LS Matza","year":"2010","unstructured":"Matza, L. S., Morlock, R., Sexton, C., Malley, K. & Feltner, D. Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder. Int. J. Methods Psychiatr. Res. 19, 223\u2013232 (2010).","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"2705_CR101","doi-asserted-by":"crossref","unstructured":"Wechsler, D. Wechsler Abbreviated Scale of Intelligence, 2nd edn (Psychological Corporation, 2011).","DOI":"10.1037\/t15171-000"},{"key":"2705_CR102","volume-title":"Wechsler Adult Intelligence Scale","author":"D Wechsler","year":"2008","unstructured":"Wechsler, D. Wechsler Adult Intelligence Scale, 4th edn (WAIS\u2013IV) (Pearson\u2019s, 2008).","edition":"4th edn (WAIS\u2013I"},{"key":"2705_CR103","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1076\/clin.12.1.43.1726","volume":"12","author":"RHB Benedict","year":"1998","unstructured":"Benedict, R. H. B., Schretlen, D., Groninger, L. & Brandt, J. Hopkins Verbal Learning Test\u2014Revised: normative data and analysis of inter-form and test\u2013retest reliability. Clin. Neuropsychol. 12, 43\u201355 (1998).","journal-title":"Clin. Neuropsychol."},{"key":"2705_CR104","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1037\/1040-3590.8.2.145","volume":"8","author":"RHB Benedict","year":"1996","unstructured":"Benedict, R. H. B., Schretlen, D., Groninger, L., Dobraski, M. & Shpritz, B. Revision of the Brief Visuospatial Memory Test: studies of normal performance, reliability, and validity. Psychol. Assess. 8, 145 (1996).","journal-title":"Psychol. Assess."},{"key":"2705_CR105","doi-asserted-by":"publisher","unstructured":"Delis, D. C., Kaplan, E. & Kramer, J. H. Delis\u2013Kaplan Executive Function System (D-KEFS) (Database record) (APA PsycTests, 2001); https:\/\/doi.org\/10.1037\/t15082-000","DOI":"10.1037\/t15082-000"},{"key":"2705_CR106","unstructured":"Conners, C. K. Conners Continuous Performance Test, 3rd edn (Multi-Health Systems, 2014); https:\/\/storefront.mhs.com\/collections\/conners-cpt-3"},{"key":"2705_CR107","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B Methodol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02705-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02705-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02705-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T08:57:57Z","timestamp":1730969877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02705-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2705"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02705-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"assertion":[{"value":"8 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.R.W. and I.H.K. are inventors on a patent application (no. 18\/467,324) related to the safety of MISTIC administration as described in the paper. J.P.C. and N.R.W. are inventors on a patent application (no. 18\/467,343) related to the use of ibogaine to treat disorders associated with brain aging. J.D., J.I. and T.M. are shareholders in Ambio Life Sciences, which offers ibogaine treatments. J.D, J.I. and T.M. are inventors in a related provisional patent application no. 63\/523,774. The application is related to adjunct treatment with various compounds during ibogaine therapy to improve safety. J.D. is founder of Terragnosis, Inc., a company dedicated to the sourcing and semisynthetic conversion of ibogaine precursors to ibogaine. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}